Inpatient Management of Autoimmune Blistering Diseases: an Update, Review, and Practical Guide
- 14 Downloads
Purpose of Review
Review the evaluation, management, and treatment of hospitalized autoimmune blistering diseases (AIBD) patients based on the current literature and expert opinion.
The cost and prevalence of hospitalization for AIBD patients are increasing in the USA. Many factors associated with hospitalization of AIBD patients are related to patient access to dermatology care. Infections are a major cause for hospital admission among AIBD patients. The use of rituximab, especially early in the disease course, has transformed the outcomes among patients with pemphigus.
After reading this review, dermatologists should be more familiar with the inpatient AIBD clinical evaluation, including the medical history, physical examination, and laboratory work-up; the management of complications of AIBD and therapy; and the treatment ladder for selecting a steroid-sparing therapy for AIBD patients.
KeywordsAutoimmune blistering disease Pemphigus Pemphigoid Inpatient dermatology
Compliance with Ethical Standards
Conflict of Interest
Dr. Russell Hall III was on the Data Safety Monitoring Board for Roche-Genentech. He also received grants and was a consultant for the following entities: Principia, Syntimmune, Cabelletta Inc., and the National Institutes of Health.
Anne Marano performed an industry sponsored clinical trial at Viela Bio for cutaneous lupus.
Adela Cardones declares no conflicts of interest.
Human and Animal Rights
All reported studies/experiments with human or animal subjects performed by the authors have been previously published and compiled with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 3.• Ren Z, Hsu DY, Brieva J, Silverberg NB, Langan SM, Silverberg JI. Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A. Br J Dermatol. 2017;176(1):87–99. https://doi.org/10.1111/bjd.14821 Demonstrates that the incidence of pemphigoid hospitalization in the United States is increasing.CrossRefGoogle Scholar
- 4.• Hsu D, Brieva J, Silverberg JI. Costs of care for hospitalization for pemphigus in the United States. JAMA Dermatology. 2016;152(6):645–54. https://doi.org/10.1001/jamadermatol.2015.5240 Demonstrates that the cost of care and incidence of pemphigus hospitalization in the United States are increasing.CrossRefGoogle Scholar
- 5.Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study. BMJ (Clinical research ed). 2008;(337):a180. https://doi.org/10.1136/bmj.a180.
- 6.Brick KE, Weaver CH, Lohse CM, Pittelkow MR, Lehman JS, Camilleri MJ, et al. Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009. J Am Acad Dermatol. 2014;71(1):92–9. https://doi.org/10.1016/j.jaad.2014.02.030.CrossRefGoogle Scholar
- 7.• Hsu DY, Brieva J, Sinha AA, Langan SM, Silverberg JI. Comorbidities and inpatient mortality for pemphigus in the U.S.A. Br J Dermatol. 2016;174(6):1290–8. https://doi.org/10.1111/bjd.14463 Many complications resulting in hospitalization for AIBD patients are infection-related or related to therapy and other medical co-morbidities. The diagnosis of pemphigus increases hospital mortality compared to the general population.CrossRefGoogle Scholar
- 10.Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138(3):370–9.Google Scholar
- 12.Gogia PP. Physical therapy modalities for wound management. Ostomy Wound Manage. 1996;42(1):46 -8, 50-2, 4.Google Scholar
- 14.• Ren Z, Narla S, Hsu DY, Silverberg JI. Association of serious infections with pemphigus and pemphigoid: analysis of the nationwide inpatient sample. J Eur Acad Dermatol Venereol. 2018;32(10):1768–76. https://doi.org/10.1111/jdv.14961 Many complications resulting in hospitalization for AIBD patients are infection-related.CrossRefGoogle Scholar
- 18.Du-Thanh A, Merlet S, Maillard H, Bernard P, Joly P, Esteve E, et al. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. Br J Dermatol. 2011;165(6):1337–43. https://doi.org/10.1111/j.1365-2133.2011.10531.x.CrossRefGoogle Scholar
- 21.Olszewska M, Kolacinska-Strasz Z, Sulej J, Labecka H, Cwikla J, Natorska U, et al. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. Am J Clin Dermatol. 2007;8(2):85–92. https://doi.org/10.2165/00128071-200708020-00004.CrossRefGoogle Scholar
- 23.Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet (London, England). 2017;389(10079):1630–8. https://doi.org/10.1016/s0140-6736(17)30560-3.CrossRefGoogle Scholar
- 25.Werth VP, Fivenson D, Pandya AG, Chen D, Rico MJ, Albrecht J, et al. Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol. 2008;144(1):25–32. https://doi.org/10.1001/archderm.144.1.25.CrossRefGoogle Scholar
- 28.Hooten J, Hall R 3rd, Cardones A. Updates on the management of autoimmune blistering diseases. Skin Therapy Lett. 2014;19(5):1–6.Google Scholar
- 29.Morel P, Guillaume JC. Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study. Ann Dermatol Venereol. 1984;111(10):925–8.Google Scholar
- 30.Kirtschig G, Middleton P, Bennett C, Murrell DF, Wojnarowska F, Khumalo NP. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010;(10):Cd002292. https://doi.org/10.1002/14651858.CD002292.pub3.
- 34.Wolverton S, editor. Comprehensive dermatologic drug therapy. 3rd ed. Edinburgh: Saunders/Elsevier; 2013.Google Scholar
- 35.Amber KT, Lamberts A, Solimani F, Agnoletti AF, Didona D, Euverman I, et al. Determining the incidence of pneumocystis pneumonia in patients with autoimmune blistering diseases not receiving routine prophylaxis. JAMA dermatology. 2017;153(11):1137–41. https://doi.org/10.1001/jamadermatol.2017.2808.CrossRefGoogle Scholar
- 36.Notaro E, Fett N, Shinohara MM. Assessment of risk and use of prophylaxis for glucocorticoidinduced-osteoporosis among dermatologists in the Pacific Northwest: a survey study. Dermatology online journal. 2017;23(9).Google Scholar
- 38.• Murrell DF, Pena S, Joly P, Marinovic B, Hashimoto T, Diaz LA, et al. Diagnosis and management of pemphigus: recommendations by an international panel of experts. J Am Acad Dermatol. 2018. https://doi.org/10.1016/j.jaad.2018.02.021 Provides an expert consensus on treatment recommendations for pemphigus, including that rituximab should be considered first-line therapy in moderate to severe pemphgius.
- 39.• Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet (London, England). 2017;389(10083):2031–40. https://doi.org/10.1016/s0140-6736(17)30070-3 The use of rituximab, particularly early in the disease course of pemphigus, has revolutionized the management of pemphigus in recent years and is more effective than use of prednisone alone.CrossRefGoogle Scholar
- 40.• Agarwal A, Hall RP 3rd, Banez LL, Cardones AR. Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: a retrospective analysis. PloS one. 2018;13(9):e0198074. https://doi.org/10.1371/journal.pone.0198074 The use of rituximab, particularly early in the disease course of pemphigus, has revolutionized the management of pemphigus in recent years and results in decreased prednisone dosing.CrossRefGoogle Scholar
- 45.Beissert S, Werfel T, Frieling U, Bohm M, Sticherling M, Stadler R, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol. 2007;143(12):1536–42. https://doi.org/10.1001/archderm.143.12.1536.CrossRefGoogle Scholar
- 49.• Amagai M, Ikeda S, Shimizu H, Iizuka H, Hanada K, Aiba S, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60(4):595–603. https://doi.org/10.1016/j.jaad.2008.09.052 Demonstrates the effectiveness of IVIg as an alternative to corticosteroids early on in the course of pemphigus.CrossRefGoogle Scholar
- 50.• Amagai M, Ikeda S, Hashimoto T, Mizuashi M, Fujisawa A, Ihn H, et al. A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid. J Dermatol Sci. 2017;85(2):77–84. https://doi.org/10.1016/j.jdermsci.2016.11.003 Demonstrates the effectiveness of IVIg as an alternative to corticosteroids early on in the course of pemphigoid.CrossRefGoogle Scholar